Patent Docs
This blawg "focuses on recent developments in biotechnology and pharmaceutical patent law. This weblog offers updates regarding changes in patent office rules and procedures that affect biotech/pharma patent prosecution, provides summaries of recent court decisions that impact biotech/pharma patent litigation and prosecution, and monitors newly filed biotech/pharma patent litigation."
Author: Donald Zuhn and Kevin Noonan are partners at McDonnell Boehnen Hulbert & Berghoff in Chicago; Chris Singer and Sherri Oslick are associates at the firm. Jason Derry is an in-house patent attorney.
Blawg Related Categories: Intellectual Property Law • Patent Law • Science & Technology Law • Associate • In-house Lawyer • Partner
Recent Posts from Patent Docs
-
In re Fallaux (Fed. Cir. 2009)
By Donald Zuhn -- On May 6, the Federal Circuit affirmed a decision by the Board of Patent Appeals and Interferences affirming the final rejection of U.S. Application No. 10/618,526 for obviousness-type double patenting. Appellants…
-
Revision of Procedures Relating to Amending PCT Applications
By Christopher P. Singer -- In a notice published in the Federal Register on Wednesday, July 1, 2009 (74 Fed. Reg. 31372), the U.S. Patent and Trademark Office published rule changes relating to amendment practice…
-
Biotech/Pharma Docket
By Suresh Pillai -- Beckman Asks for Dismissal in Patent Dispute with Sequenom Following the completion of a Markman hearing in a dispute with Sequenom Inc. concerning patents covering genotyping methods, Beckman Coulter has asked…
-
FierceBiotech Announces "Fierce 15" for 2009
By Christopher P. Singer -- FierceBiotech published its annual "Fierce 15" list of what it considers to be among the most promising of the up-and-coming companies in the biotechnology industry. FierceBiotech, a daily biotech industry…
-
Follow-on Biologics in the News - No. 4
By Donald Zuhn -- IPO Continues to Support 14-Year Exclusivity Period The Intellectual Property Owners Association (IPO), reporting on last week's announcement that the White House believes a 7-year data exclusivity period "strikes the appropriate…
-
USPTO Initiates Patent Prosecution Highway Pilot Program with Finland Patent Office
By Christopher P. Singer -- In June 29, 2009 press release, the U.S. Patent and Trademark Office announced that it has agreed with the National Board of Patents and Registration of Finland (NBPR) to establish…
-
Court Report
By Sherri Oslick -- About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Dey, L.P. et al.…
-
Conference & CLE Calendar
June 29-30 - Product and Pipeline Enhancement for Generics (Marcus Evans) - Washington, DC July 6, 2009 - Prior Art & Obviousness 2009: The PTO & CAFC Perspective on Patent Law Sections 102 & 103…
-
White House Recommends 7-Year Data Exclusivity Period for Follow-on Biologics
By Donald Zuhn -- Reuters reports that the White House sent a letter to Rep. Henry Waxman (D-CA), the Chairman of the House Energy and Commerce Committee, on Thursday stating that a follow-on biologics regulatory…
-
Is Venezuela the new Thailand?
By Kevin E. Noonan -- A great deal has been written over the past week about Venezuela's new patented drug policy. Last Saturday, President Hugo Chavez (at right) announced that his government would "shake up"…